secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALISADE BIO, INC. (PALI)
CIK:        0001357459
Form:       8-K
Filed at:   2022-12-16T23:59:59+00:00
Accession:  0001493152-22-035770
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palisade Bio stops Phase 2 LB1148 trial early; topline data due H1 2023
-----------------------------------------------------------------------

- Enrolled 35 of 70 planned patients in Phase 2 PROFILE study for post-surgical adhesions; voluntarily halting further enrollment.
- Of those, 31 completed first surgery and 9 completed second surgery (key inflection point for data).
- Topline data from the 35 patients expected in first half of 2023.
- Company designing a dose optimization study to refine dosing; enrollment anticipated in H1 2023.
- CMO Herbert Slade stated collected data is sufficient for evaluation and to guide next steps.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357459/000149315222035770/0001493152-22-035770-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357459/000149315222035770/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-035770

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer